Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.46 |
| ▸ | INSR | P06213 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.42 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30173407 | 1.00 | IGF1R (0.49) | IGF1REGFRCDK7CDK9ALK | |
| SCHEMBL25056225 | 0.87 | IGF1R (0.49) | IGF1REGFRCDK7CDK9ALK | |
| SCHEMBL11916362 | 0.86 | CDK7 (0.60) | IGF1REGFRCDK7CDK9ALK | |
| SCHEMBL29400320 | 0.86 | CDK7 (0.60) | IGF1REGFRCDK7CDK9ALK | |
| SCHEMBL14240767 | 0.85 | CDK7 (0.48) | IGF1REGFRCDK7CDK9ALK | |
| SCHEMBL30503695 | 0.85 | CDK7 (0.48) | IGF1REGFRCDK7CDK9ALK | |
| SCHEMBL24179135 | 0.85 | MEN1 (0.43) | IGF1REGFRCDK7CDK9ALK | |
| SCHEMBL29975976 | 0.85 | EGFR (0.42) | IGF1REGFRCDK7CDK9ALK | |
| SCHEMBL23153875 | 0.85 | EGFR (0.42) | IGF1REGFRCDK7CDK9ALK | |
| SCHEMBL25056368 | 0.84 | IGF1R (0.46) | IGF1REGFRCDK7CDK9ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116870016-B | Heteroaromatic compound and medical application thereof | 希格生科（深圳）有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-116888108-B | Novel EGFR degradation agent | 上海齐鲁制药研究中心有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117425646-A | Phosphono derivative, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-117412981-A | Phosphine oxide derivative and preparation method and application thereof | 希格生科（深圳）有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-116888108-A | Novel EGFR degradation agent | 上海齐鲁制药研究中心有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116870016-A | Heteroaromatic compound and medical application thereof | 希格生科（深圳）有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | QILU PHARMACEUTICAL CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| EP-2704572-B1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMA INC (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| WO-2013169401-A1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| WO-2012151561-A1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | BRAF, RAF1, EGFR | IGF1R 675/4885EGFR 3/4885CDK7 315/4885 |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, MKI67, ERBB2 | IGF1R 73/4885EGFR 1/4885CDK7 56/4885 |
| US-20230192734-A1 | TRICYCLIC COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | IGF1R 12/4885EGFR 1/4885CDK7 52/4885 |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | IGF1R 160/4885EGFR 1/4885CDK7 143/4885 |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, MKI67, ERBB2 | IGF1R 73/4885EGFR 1/4885CDK7 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.